Patritumab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData, Phase III drugs for Non-Small Cell Lung Cancer have a 48% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Patritumab deruxtecan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Patritumab deruxtecan overview

Patritumab deruxtecan (U-31402) is under development for the treatment of HER3-positive metastatic or unresectable breast cancer, human epidermal growth factor receptor 2 negative breast cancer, squamous or non-squamous non-small cell lung cancer, melanoma, intestinal cancer, ovarian cancer, cholangiocarcinoma, prostate cancer and triple negative breast cancer. It is administered intravenously. The drug candidate is a humanized anti-HER3 antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). It is developed based on proprietary payload and linker-payload technology. It was also under development for bladder cancer and skin cancer.

It was under development for the treatment of metastatic colorectal cancer, colon cancer and rectal adenocarcinoma. 

Daiichi Sankyo overview

Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.

For a complete picture of Patritumab deruxtecan’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.